Evidence map›Paper›PMID 34761777›Full record

ArticleDalton transactions (Cambridge, England : 2003)2021

Umbelliferyloxymethyl phosphonate compounds-weakly binding zinc ionophores with neuroprotective properties.

Sebastien Guesne, Laura Connole, Stephanie Kim, Majid Motevalli, Lesley Robson, Adina T Michael-Titus, Alice Sullivan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sebastien GuesneDept. of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK. a.c.sullivan@qmul.ac.uk.
Laura ConnoleBlizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, Mile End Road, London E1 4NS, UK.
Stephanie KimDept. of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK. a.c.sullivan@qmul.ac.uk.
Majid MotevalliDept. of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK. a.c.sullivan@qmul.ac.uk.
Lesley RobsonBlizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, Mile End Road, London E1 4NS, UK.
Adina T Michael-TitusBlizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, Mile End Road, London E1 4NS, UK.
Alice SullivanDept. of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK. a.c.sullivan@qmul.ac.uk.ORCID http://orcid.org/0000-0002-1718-0947
Queen Mary University of London · GB

Funding

Medical Research Council G0802503
6 · The paper itself

Abstract

Umbelliferone is a member of the coumarin family of compounds which are known for diverse pharmacological activity including in targets relevant to Alzheimers disease, AD. The toxicity associated with some forms of the amyloid protein, Aβ, and the role of Zn

Indexed as

Amyloid beta-PeptidesAnimalsCells, CulturedIonophoresNeuroprotective AgentsOrganophosphonatesRatsRats, Sprague-DawleyZincAmyloid beta-PeptidesIonophoresNeuroprotective AgentsOrganophosphonatesZinc

Identifiers

PMID34761777
PMCPMC8631114
OpenAlexW3212400899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.